Dapagliflozin (Forxiga®) Versus Glipizide As Add-On Therapies In Type 2 Diabetes Mellitus (T2dm); An Update of The Cost-Effectiveness Based On Long-Term Clinical Evidence From Uk Nhs Perspective
Nov 1, 2014, 00:00
10.1016/j.jval.2014.08.690
https://www.valueinhealthjournal.com/article/S1098-3015(14)02620-5/fulltext
Title :
Dapagliflozin (Forxiga®) Versus Glipizide As Add-On Therapies In Type 2 Diabetes Mellitus (T2dm); An Update of The Cost-Effectiveness Based On Long-Term Clinical Evidence From Uk Nhs Perspective
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(14)02620-5&doi=10.1016/j.jval.2014.08.690
First page :
A343
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
110